JP7262599B2 - タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物 - Google Patents

タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物 Download PDF

Info

Publication number
JP7262599B2
JP7262599B2 JP2021548608A JP2021548608A JP7262599B2 JP 7262599 B2 JP7262599 B2 JP 7262599B2 JP 2021548608 A JP2021548608 A JP 2021548608A JP 2021548608 A JP2021548608 A JP 2021548608A JP 7262599 B2 JP7262599 B2 JP 7262599B2
Authority
JP
Japan
Prior art keywords
group
methyl
compound
pyrimidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021548608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521901A (ja
Inventor
テ・ボ・シム
ウ・ヨン・ホ
チ・マン・ソン
サンディップ・セングプタ
チャン・スン・パク
スン・ヘ・チェ
ハン・ナ・チョ
イン・ジェ・シン
Original Assignee
コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー filed Critical コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー
Publication of JP2022521901A publication Critical patent/JP2022521901A/ja
Application granted granted Critical
Publication of JP7262599B2 publication Critical patent/JP7262599B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021548608A 2019-02-18 2020-02-17 タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物 Active JP7262599B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020190018704A KR20200100429A (ko) 2019-02-18 2019-02-18 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
KR10-2019-0018704 2019-02-18
PCT/KR2020/002213 WO2020171499A1 (fr) 2019-02-18 2020-02-17 Nouveau dérivé de pyrido[3,4-d]pyrimidin-8-one ayant une activité inhibitrice de protéine kinase, et composition pharmaceutique pour prévenir, soulager ou traiter le cancer, comprenant celui-ci

Publications (2)

Publication Number Publication Date
JP2022521901A JP2022521901A (ja) 2022-04-13
JP7262599B2 true JP7262599B2 (ja) 2023-04-21

Family

ID=72143523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548608A Active JP7262599B2 (ja) 2019-02-18 2020-02-17 タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物

Country Status (11)

Country Link
US (1) US20220135559A1 (fr)
EP (1) EP3929195A4 (fr)
JP (1) JP7262599B2 (fr)
KR (1) KR20200100429A (fr)
CN (1) CN113646307B (fr)
AU (1) AU2020225048B2 (fr)
BR (1) BR112021016132A2 (fr)
CA (1) CA3130568A1 (fr)
MX (1) MX2021009868A (fr)
NZ (1) NZ779245A (fr)
WO (1) WO2020171499A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507669A (ja) * 2020-01-15 2023-02-24 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (fr) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
EP3908283A4 (fr) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
EP4021444A4 (fr) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof
WO2023239165A1 (fr) * 2022-06-08 2023-12-14 한국화학연구원 Dérivés de phénylsulfonamide, leur procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525292A (ja) 2006-01-31 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー ７ｈ−ピリド［３，４−ｄ］ピリミジン−８−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014080291A3 (fr) 2012-11-21 2014-09-12 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2018113584A1 (fr) 2016-12-19 2018-06-28 上海和誉生物医药科技有限公司 Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique
WO2018130184A1 (fr) 2017-01-13 2018-07-19 江苏恒瑞医药股份有限公司 Dérivé de 1,2,4-triazine-3-amine, son procédé de préparation et son utilisation en médecine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1860118A (zh) * 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US7662607B2 (en) * 2003-07-30 2010-02-16 New Century Pharmaceuticals, Inc. Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
EP2112150B1 (fr) * 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
US20110269758A1 (en) * 2008-07-03 2011-11-03 Merck Patent Gmbh Naphthyridinones as protein kinase inhibitors
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
ITBO20130393A1 (it) 2013-07-23 2015-01-24 Ima Ind Srl Dispositivo di saldatura ad ultrasuoni
KR101897631B1 (ko) * 2016-08-10 2018-09-12 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1H)-온 골격의 유레아 화합물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525292A (ja) 2006-01-31 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー ７ｈ−ピリド［３，４−ｄ］ピリミジン−８−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014080291A3 (fr) 2012-11-21 2014-09-12 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2018113584A1 (fr) 2016-12-19 2018-06-28 上海和誉生物医药科技有限公司 Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique
WO2018130184A1 (fr) 2017-01-13 2018-07-19 江苏恒瑞医药股份有限公司 Dérivé de 1,2,4-triazine-3-amine, son procédé de préparation et son utilisation en médecine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hanna CHO et al.，First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia，J. MED. CHEM.，2018年，vol.61, no.18，p.8353-8373

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507669A (ja) * 2020-01-15 2023-02-24 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物
JP7531595B2 (ja) 2020-01-15 2024-08-09 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物

Also Published As

Publication number Publication date
JP2022521901A (ja) 2022-04-13
NZ779245A (en) 2024-08-30
KR20200100429A (ko) 2020-08-26
EP3929195A1 (fr) 2021-12-29
CN113646307B (zh) 2024-07-30
WO2020171499A1 (fr) 2020-08-27
AU2020225048B2 (en) 2023-02-23
EP3929195A4 (fr) 2022-11-30
MX2021009868A (es) 2022-01-04
CN113646307A (zh) 2021-11-12
AU2020225048A1 (en) 2021-09-16
BR112021016132A2 (pt) 2021-10-13
US20220135559A1 (en) 2022-05-05
CA3130568A1 (fr) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7262599B2 (ja) タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物
JP7531595B2 (ja) ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物
US10350210B2 (en) EGFR and ALK dual inhibitor
JP7427098B2 (ja) タンパク質キナ－ゼ阻害活性を有する７－アミノ－３，４－ジヒドロピリミドピリミジン－２－オン誘導体およびこれを含む治療用薬学組成物
JP5562256B2 (ja) 新規化合物、その使用及び製造
JP2019527725A (ja) ４位置換アミノイソキノリン誘導体
WO2017114383A1 (fr) Nouvel inhibiteur de kinase contre un egfr de type sauvage et un egfr muté
CN102365277A (zh) Jun n-末端激酶抑制剂
US10975082B2 (en) Inhibitor of FLT3 kinase and use thereof
WO2020156283A1 (fr) Composé alkynylpyrimidine ou alkynylpyridine, et composition et application de celui-ci
KR102319676B1 (ko) 피롤로피리미딘, 피롤로피리딘, 인다졸 화합물 유도체 및 이를 포함하는 치료용 약학 조성물
TWI803541B (zh) 對於蛋白激酶具抑制活性之噻吩并[3,2-d]嘧啶化合物
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
US11530221B2 (en) Pyrimido[4,5-d]pyrimidin-2-one derivatives as protein kinase inhibitors
KR102205619B1 (ko) 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
RU2780168C1 (ru) Новое производное пиридо [3,4-d] пиримидин-8-она, обладающее ингибирующей протеинкиназы активностью, и фармацевтическая композиция для предупреждения, облегчения или лечения рака, содержащее указанное выше
KR102133569B1 (ko) 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR102329723B1 (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
KR101721128B1 (ko) 우레이도벤조티아졸 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230411

R150 Certificate of patent or registration of utility model

Ref document number: 7262599

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150